CN118591538A - 吡嗪酰胺衍生物 - Google Patents

吡嗪酰胺衍生物 Download PDF

Info

Publication number
CN118591538A
CN118591538A CN202380018582.3A CN202380018582A CN118591538A CN 118591538 A CN118591538 A CN 118591538A CN 202380018582 A CN202380018582 A CN 202380018582A CN 118591538 A CN118591538 A CN 118591538A
Authority
CN
China
Prior art keywords
carboxamide
pyrazine
indol
amino
methylpropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018582.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·Y·黄
T·M·小基拉内
V·马克思
A-C·玛塔
C·R·萨尔科
B·R·塔夫特
横川文昭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN118591538A publication Critical patent/CN118591538A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fuel Cell (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380018582.3A 2022-03-24 2023-03-22 吡嗪酰胺衍生物 Pending CN118591538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269879P 2022-03-24 2022-03-24
US63/269,879 2022-03-24
PCT/IB2023/052827 WO2023180964A1 (en) 2022-03-24 2023-03-22 Pyrazine amide derivatives

Publications (1)

Publication Number Publication Date
CN118591538A true CN118591538A (zh) 2024-09-03

Family

ID=85979464

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018582.3A Pending CN118591538A (zh) 2022-03-24 2023-03-22 吡嗪酰胺衍生物

Country Status (10)

Country Link
US (1) US20250197376A1 (https=)
EP (1) EP4499631A1 (https=)
JP (1) JP2025509917A (https=)
CN (1) CN118591538A (https=)
AU (1) AU2023240513A1 (https=)
CA (2) CA3181279A1 (https=)
CO (1) CO2024010469A2 (https=)
DO (1) DOP2024000149A (https=)
WO (1) WO2023180964A1 (https=)
ZA (1) ZA202405048B (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137081A2 (en) * 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
ES2921576T3 (es) * 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT2925757T (lt) * 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
WO2016089977A1 (en) * 2014-12-03 2016-06-09 Celgene Corporation Substituted indazole compounds, compositions thereof, and methods of treatment therewith
CN110023312A (zh) * 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
WO2018081863A1 (en) * 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
EP3790878A1 (en) * 2018-05-11 2021-03-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Quinoline compounds and their preparation and use as antimalarial agents

Also Published As

Publication number Publication date
WO2023180964A1 (en) 2023-09-28
ZA202405048B (en) 2025-09-25
EP4499631A1 (en) 2025-02-05
CA3181279A1 (en) 2023-09-24
JP2025509917A (ja) 2025-04-11
US20250197376A1 (en) 2025-06-19
CO2024010469A2 (es) 2024-08-08
AU2023240513A1 (en) 2024-07-18
CA3251003A1 (en) 2023-09-28
DOP2024000149A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
TWI787018B (zh) 轉染過程重排之抑制劑
US20230174555A1 (en) Naphthyridine compounds as inhibitors of kras
IL297165A (en) Soysag tricyclic CRS inhibitors
WO2021088945A1 (zh) 作为shp2抑制剂的化合物及其应用
WO2023151621A1 (zh) 具有抗kras突变肿瘤活性的化合物
JP7106659B2 (ja) インドール－２、３－ジオキシゲナーゼ阻害剤としてのスピロ化合物
KR20220066290A (ko) Perk 억제 피롤로피리미딘 화합물
CA2932870C (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
WO2024199108A1 (zh) 作为wrn解旋酶抑制剂的化合物
KR20210022645A (ko) N-치환된 테트라히드로티에노피리딘 유도체 및 이의 용도
EP3810598A1 (en) Cyanotriazole compounds and uses thereof
CN110678468B (zh) 用于治疗寄生虫病的5,6-稠合双环化合物及其组合物
TW201713661A (zh) 化合物
CN118591538A (zh) 吡嗪酰胺衍生物
CN115667218A (zh) 激酶抑制剂
CN119998274A (zh) Ulk抑制剂
WO2021078120A1 (en) Compounds and compositions for the treatment of parasitic diseases
CN105189485B (zh) 作为抗疟剂的新型丙烯酰胺衍生物
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
TWI827869B (zh) 作為蛋白激酶抑制劑的取代的吡咯並[2,3-b]吡啶及吡唑並[3,4-b]吡啶衍生物
WO2025163522A1 (en) Cyanotriazole compounds and uses thereof
TW201736373A (zh) 作為免疫調節劑的三並環化合物
CN120615094A (zh) 一种作为治疗神经系统疾病和肿瘤的多环化合物
HK1261174B (zh) 内磺醯胺化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination